Genomtec S.A.
GMT.WA
Warsaw Stock Exchange4.75
PLN
+0.05
- -
Genomtec S.A.
GMT.WA
(Warsaw Stock Exchange)
Recent
price
4.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genomtec S.A. is a Poland-based medical technology company specializing in the research, development, and commercialization of innovative molecular diagnostic solutions. Founded in 2016 and headquartered in Wrocław, the company operates primarily within the clinical diagnostics industry, offering advanced genetic testing platforms and rapid diagnostic tools. Its flagship product, Genomtec ID, is a mobile, point-of-care genetic testing platform that enables rapid, precise detection of pathogens and genetic mutations without the need for complex laboratory workflows. The platform uses proprietary Streamlined Nucleic Acid Amplification Technology (SNAAT) and includes CE-IVD certified assays such as the GenomtecID Respiratory Panel 5-Plex for detecting respiratory viruses and bacteria. The company also advances the OncoSNAAT project, which focuses on oncological diagnostics using single nucleotide polymorphism (SNP) detection based on isothermal amplification techniques. Recent significant developments include the filing of a second patent application for the OncoSNAAT oncology project, reflecting advancements in single-nucleotide genetic change detection technology protected under international patent protocols. In 2024, Genomtec undertook a strategic organizational restructuring to accelerate merger and acquisition (M&A) activities, including spinning off key projects like Genomtec ID and OncoSNAAT into separate special purpose vehicles. This move aims to enhance the investment appeal and flexibility for potential partners and investors. The company has engaged in high-level industry conferences, signed non-disclosure agreements with prospective M&A partners, and is actively negotiating commercialization strategies ranging from licensing agreements to potential sales of business units or the entire company. Additionally, it appointed Leroy Huntley to its management board in mid-2025 to support these transformative efforts. Genomtec operates internationally, with research and engineering offices including a presence in the United Kingdom, targeting global markets in molecular diagnostics, oncology, and food safety diagnostics. Its technology emphasizes portable, high-speed, and accurate molecular analysis suitable for primary care clinics, pharmacies, hospitals, and emergency departments. The company's innovative approach focuses on smaller analyzer size, low energy consumption, and affordability, which positions its products competitively in the expanding point-of-care diagnostics market. Overall, Genomtec S.A. leverages proprietary molecular biology techniques and mobile platform technology to deliver cutting-edge genetic diagnostic solutions, supported by strategic restructuring and robust intellectual property development to drive growth and market penetration across Europe and potentially broader regions. The company continues to develop its oncology diagnostic capabilities while advancing commercialization and partnership strategies to maximize shareholder value.